Figure 4
Figure 4. Allogeneic TCR-transduced CD8+ T cells fail to induce GVL when given later after HCT. A total of 40 × 106 TCR gene-transduced allogeneic (B10.A) or syngeneic (B6) T cells were adoptively transferred late (56 days) after HCT into either allogeneic (B10.A → B6) or syngeneic (B6 → B6) transplant recipients. (A) On days 1, 3, and 7 after AT, peripheral blood was monitored for GFP expressing allogeneic (●) or syngeneic (○) TCR-transduced T cells. P values between cohorts that received allogeneic or syngeneic T cells: P = not significant (n.s.) for day 1. ***P < .001 for day 3. ***P < .0001 for day 7. n = 10 to 18; pooled data from 2 independent experiments are shown. (B) Mice received AT with either allogeneic (■) or syngeneic (□) TCR-transduced T cells or PBS (*) 56 days after HCT. Three days after AT, mice were challenged with 1.2 × 106 C1498-OVA cells intravenously. P < .005 between TCR-transduced syngeneic T cells and PBS. P < .05 between TCR-transduced allogeneic and syngeneic T cells. P = not significant (n.s.) between TCR-transduced allogeneic T cells and PBS. n = 8 per group. (C) Mice received AT with TCR-transduced allogeneic T cells (■) as in panel B or naive DLI (▴) without subsequent leukemia challenge. Clinical GVHD scoring was performed weekly for 8 weeks after AT (n = 8-10 per group). P = not significant (n.s.) between cohorts that received TCR-transduced allogeneic T cells or DLI.

Allogeneic TCR-transduced CD8+ T cells fail to induce GVL when given later after HCT. A total of 40 × 106 TCR gene-transduced allogeneic (B10.A) or syngeneic (B6) T cells were adoptively transferred late (56 days) after HCT into either allogeneic (B10.A → B6) or syngeneic (B6 → B6) transplant recipients. (A) On days 1, 3, and 7 after AT, peripheral blood was monitored for GFP expressing allogeneic (●) or syngeneic (○) TCR-transduced T cells. P values between cohorts that received allogeneic or syngeneic T cells: P = not significant (n.s.) for day 1. ***P < .001 for day 3. ***P < .0001 for day 7. n = 10 to 18; pooled data from 2 independent experiments are shown. (B) Mice received AT with either allogeneic (■) or syngeneic (□) TCR-transduced T cells or PBS (*) 56 days after HCT. Three days after AT, mice were challenged with 1.2 × 106 C1498-OVA cells intravenously. P < .005 between TCR-transduced syngeneic T cells and PBS. P < .05 between TCR-transduced allogeneic and syngeneic T cells. P = not significant (n.s.) between TCR-transduced allogeneic T cells and PBS. n = 8 per group. (C) Mice received AT with TCR-transduced allogeneic T cells (■) as in panel B or naive DLI (▴) without subsequent leukemia challenge. Clinical GVHD scoring was performed weekly for 8 weeks after AT (n = 8-10 per group). P = not significant (n.s.) between cohorts that received TCR-transduced allogeneic T cells or DLI.

Close Modal

or Create an Account

Close Modal
Close Modal